0.00Open0.00Pre Close0 Volume0 Open Interest30.00Strike Price0.00Turnover285.64%IV-185.17%PremiumDec 20, 2024Expiry Date19.48Intrinsic Value100Multiplier10DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9789Delta0.0129Gamma0.54Leverage Ratio-0.0095Theta-0.0034Rho-0.53Eff Leverage0.0009Vega
Y-mAbs Therapeutics Stock Discussion
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
Y-mAbs Therapeutics (NASDAQ: YMAB)presented preclinical data and trial progress for its CD38-SADA platform at the 2024 ASH Annual Meeting. The preclinical data demonstrated selective binding and anti-tumor efficacy of CD38-SADA when used with Lutetium 177-DOTA in treating Non-Hodgkin Lymphoma (NHL).
The company also...
No comment yet